RDY - Dr. Reddy's Laboratories Limited

NYSE - NYSE Delayed Price. Currency in USD

Dr. Reddy's Laboratories Limited

8-2-337, Road No. 3
Banjara Hills
Hyderabad 500034
91 40 4900 2900

IndustryDrug Manufacturers - Other
Full Time Employees22,671

Key Executives

NameTitlePayExercisedYear Born
Mr. Gunupati Venkateswara Prasad B.Sc. (Chem. Eng.), M.S. (Indl. Admn.)Co-Chairman, MD & CEO1.51MN/A1960
Mr. Kallam Satish Reddy B.Tech., M.S.Chairman1.12MN/A1967
Mr. Saumen Chakraborty B.Sc. (H), MBA-IIMPres, CFO and Global Head of Information Technology & Bus. Process ExcellenceN/AN/A1961
Dr. Sripada Chandrasekhar Mba., Ph.D.Pres & Global Head of HR340.78kN/A1957
Mr. Abhijit Mukherjee B.Tech. (Chem.)Chief Operating OfficerN/AN/A1958
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2017, this segment had 16 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies; and strategic collaboration with Amgen Inc. for the commercialization of oncology and osteoporosis medicines. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Corporate Governance

Dr. Reddy's Laboratories Limited’s ISS Governance QualityScore as of March 1, 2018 is 10. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.